<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01641250</url>
  </required_header>
  <id_info>
    <org_study_id>BP28085</org_study_id>
    <secondary_id>2012-001027-12</secondary_id>
    <nct_id>NCT01641250</nct_id>
  </id_info>
  <brief_title>A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia</brief_title>
  <official_title>Open Label, Multicenter, Dose Escalation Phase 1a/b Study of RO5429083, Administered as Intravenous Infusion Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia (AML).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This multi-center, open-label study will evaluate the safety, pharmacokinetics,
      pharmacodynamics and efficacy of RO5429083 alone and in combination with cytarabine in
      patients with acute myelogenous leukemia. In Part A, patients will receive multiple
      escalating doses of RO5429083 intravenously. In Part B, patients will receive RO5429083 plus
      up to 4 cycles of cytarabine (1000 mg/m2 iv daily for 5 consecutive days). Anticipated time
      on study treatment is until disease progression or unacceptable toxicity occurs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence of adverse events (including maximum tolerated dose/optimal biological dose)</measure>
    <time_frame>approximately 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response according to hematologic malignancy assessments</measure>
    <time_frame>approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics o RO5429083 alone and in combination with cytarabine: Area under the concentration-time curve (AUC)</measure>
    <time_frame>Pre-dose and up to 96 hrs post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of cytarabine in combination with RO5429083: Area under the concentration-time curve (AUC)</measure>
    <time_frame>Pre-dose and up to 24 hrs post-dose, Cycles 1 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Biomarker levels in blood/bone marrow</measure>
    <time_frame>Pre-dose and up to 96 hrs post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Myelogenous Leukemia, Acute</condition>
  <arm_group>
    <arm_group_label>Part A: RO5429083</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: RO5429083 + cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5429083</intervention_name>
    <description>Multiple escalating doses</description>
    <arm_group_label>Part A: RO5429083</arm_group_label>
    <arm_group_label>Part B: RO5429083 + cytarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>1000 mg/m2 iv daily for 5 consecutive days, up to 4 cycles</description>
    <arm_group_label>Part B: RO5429083 + cytarabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, &gt;/= 18 years of age

          -  Histologically or cytologically confirmed, acute myelogenous leukemia (all subtypes
             except acute promyelotic leukemia) according to WHO criteria

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

          -  All non-hematological adverse events of any prior chemotherapy, surgery, or
             radiotherapy must have resolved to NCI-CTC AE Grade &lt; 2, except alopecia

          -  Adequate hepatic and renal function

          -  Patient must be willing to submit blood and bone marrow samples for PK and PD analyses
             and exploratory biomarkers

        Exclusion Criteria:

          -  Patients receiving any other investigational or commercial agents or therapies
             administered with the intention to treat their malignancy within 14 days of first
             receipt of study drug, with the exception of hydroxyurea

          -  History of allergic reactions attributed to components of cytarabine and/or the
             formulated product

          -  Current evidence of CNS leukemia

          -  Increased QTc interval (QTc &gt; 470 ms), baseline resting bradycardia &lt; 45 beats per
             minute, or baseline resting tachycardia &lt; 100 beats per minute

          -  Family history of long QT syndrome or other risk factors for torsades de pointes,
             and/or the use of concomitant medications that prolong QT/QTc interval

          -  Uncontrollable intercurrent illness

          -  Pregnant or breast-feeding women

          -  HIV-positive patients receiving anti-retroviral therapy

               -  Patients who refuse to potentially receive blood products and/or have a
                  hypersensitivity to blood products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2012</study_first_submitted>
  <study_first_submitted_qc>July 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2012</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

